Blood Test News and Research

RSS

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism Conference, leading arthritis researchers presented important data on Augurex's rheumatoid arthritis biomarker blood test and novel drug target.

30 May 2011

Phadia ImmunoCAP Specific IgE blood test used in largest cross-sectional allergy study

Phadia, the worldwide leader of in vitro allergy diagnostics, is pleased to contribute to the largest cross-sectional allergy study ever conducted through the use of its ImmunoCAP Specific IgE blood test, the market leading in vitro allergy diagnostic test.

27 May 2011

Quest Diagnostics announces results of largest ImmunoCAP cross-sectional allergy study

ImmunoCAP, the worldwide leader of in vitro allergy diagnostics, is pleased to present the results of the largest cross-sectional allergy study ever conducted. The landmark study, announced today by Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information, and services, includes test results from over 2 million patients.

From Quest Diagnostics 27 May 2011

Recent ACS podcast focuses on new rapid blood test that can detect MRSA infections

The latest episode in the American Chemical Society's award-winning podcast series, "Global Challenges/Chemistry Solutions," focuses on new blood test that can quickly tell whether patients are infected with an antibiotic-resistant bacterium that's become a global threat, significantly improving treatment.

25 May 2011

Vectra DA blood test may help predict patients' response to rheumatoid arthritis therapy

Crescendo Bioscience- today announced data indicating that Vectra- DA, a first-in-class multi-biomarker blood test used to assess rheumatoid arthritis disease activity, provides physicians with an objective measure which may help determine whether patients are responding to therapy.

25 May 2011

Thermo Fisher Scientific to acquire Phadia for €2.47 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics, from European private equity firm Cinven, for €2.47 billion (or approximately $3.5 billion) in cash.

From Thermo Fisher Scientific Inc. 19 May 2011

Simple home-based colon cancer screening test can prevent many unnecessary deaths in Canada

Use of a simple, at-home screening test by Canadians can prevent many unnecessary colorectal cancer deaths, according to a special report about colorectal cancer in Canadian Cancer Statistics 2011 released today by the Canadian Cancer Society, in collaboration with the Public Health Agency of Canada and Statistics Canada.

19 May 2011

Early childhood food allergies increase risk of severe allergy-related conditions and asthma later in life

Early results from the largest cross-sectional national allergy study ever conducted, to be released later this month, demonstrate that food allergies commonly occur in infants and toddlers, while environmental allergies, such as to dust, ragweed and mold, are more common in older children and adults.

From Quest Diagnostics 18 May 2011

Restrictive gadolinium-based contrast agent guidelines help prevent nephrogenic systemic fibrosis

A simple blood test may help prevent a serious complication associated with a contrast agent commonly used in MRI exams, according to a study published in the July issue of Radiology.

18 May 2011

Researchers lay foundation for future lung cancer detection test

Scientists working with Professor Dr. Joachim L. Schultze have identified over 480 molecules whose concentration in the blood changes when a person develops lung cancer. These molecules are present in the blood cells either in increased or decreased quantities. "In lung cancer patients, typical patterns which can be detected with a measuring program thus emerge", explains Prof. Schultze.

17 May 2011

Life expectancy blood test not popular with experts

According to scientists and medical ethicist there are hidden dangers of a new blood test for determining how fast someone is ageing. The test costs £435 test and is due to go on sale to the general public in Britain later this year, measures the length of a person's telomeres, the structures on the tips of the chromosomes which get progressively shorter with age. Short telomeres are linked with age-related diseases and premature death.

17 May 2011

Gene variant linked to infertility in women

A variation in a gene involved in regulating cholesterol in the bloodstream also appears to affect progesterone production in women, making it a likely culprit in a substantial number of cases of their infertility, a new study from Johns Hopkins researchers suggests.

16 May 2011

Bonn researchers to develop new blood test for lung cancer diagnosis

A person's blood reveals whether he or she has lung cancer: this has been demonstrated by researchers at the University of Bonn. In collaboration with colleagues at the Cologne University Hospital, they are developing a blood test for smokers which could save human lives in the future, since the earlier a lung tumor is detected, the better the chances of survival are.

16 May 2011

Researchers identify miRNA in blood serum of lung cancer patients

Researchers have identified characteristic patterns of molecules called microRNA in the blood of people with lung cancer that might reveal both the presence and aggressiveness of the disease, and perhaps who is at risk of developing it.

13 May 2011

Study: OVA1 blood test can accurately predict ovarian cancer in women with pelvic masses

A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of Obstetrics and Gynecology guidelines for determining the likelihood that an ovarian mass is cancerous prior to surgery would accurately identify more women with ovarian cancer if the OVA1 blood test were used in place of the currently recommended CA 125 blood test.

From Quest Diagnostics 13 May 2011

Genetic test to identify women at higher risk of breast cancer could reduce risks associated with screening

Calculating individual genetic cancer risk and taking age into account could mean fewer women would need to be screened for breast cancer, according to research published in the British Journal of Cancer1.

11 May 2011

U.S. veterans over 70 and older can benefit from current colon cancer screening methods

A new study of U.S. veterans ages 70 and older finds that the healthiest get the most benefit from current colon cancer screening methods. However, for many less healthy veterans the burdens of screening may outweigh the benefits.

10 May 2011

Epigenomics presents Septin9 blood test study data in colorectal cancer at DDW 2011

Epigenomics AG, the cancer molecular diagnostics company, reports that Dr. Uri Ladabaum, Associate Professor in the Department of Gastroenterology and Hepatology at the School of Medicine of Stanford University, has presented the results of a health economic analysis of potential future colorectal cancer screening with Septin9 blood tests at the ongoing Digestive Disease Week 2011.

9 May 2011

Epigenomics, Life Technologies enter supply agreement for second-generation colorectal cancer blood test

Epigenomics AG, the cancer molecular diagnosis company, today announced the signing of a supply agreement with Life Technologies Corporation, a global provider of innovative life science solutions.

7 May 2011

Despite expanded Medicare coverage racial disparities continue in colorectal cancer screening

Despite expanded Medicare coverage for colorectal cancer screening tests, lower rates still exist among blacks and Hispanics compared to other ethnic groups, according to research published in Cancer, Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

6 May 2011